Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • Log out
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Comparative Effects of Thiazolidinediones on in Vitro P450 Enzyme Induction and Inhibition

Jasminder Sahi, Christopher B. Black, Geraldine A. Hamilton, Xianxian Zheng, Summer Jolley, Kelly A. Rose, Darryl Gilbert, Edward L. LeCluyse and Michael W. Sinz
Drug Metabolism and Disposition April 2003, 31 (4) 439-446; DOI: https://doi.org/10.1124/dmd.31.4.439
Jasminder Sahi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher B. Black
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Geraldine A. Hamilton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xianxian Zheng
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Summer Jolley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kelly A. Rose
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Darryl Gilbert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward L. LeCluyse
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael W. Sinz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Rosiglitazone and pioglitazone are thiazolidinediones used for treatment of noninsulin-dependent diabetes mellitus. These compounds, along with troglitazone, were evaluated for the ability to induce cytochrome P450 enzymes (P450) in primary human hepatocyte cultures and to inhibit P450 in human microsomes. In induction studies, all three thiazolidinediones caused a dose-dependent increase in CYP3A4 activity and immunoreactive protein. While troglitazone was the most potent, rosiglitazone and pioglitazone generally exceeded troglitazone in absolute CYP3A4 activity achieved at concentrations ≥10 μM. A comparable concentration-dependent increase in CYP2B6 immunoreactive protein was observed with all three thiazolidinediones. Microarray analysis revealed rifampin > troglitazone > pioglitazone > rosiglitazone in terms of CYP3A4 mRNA induction potential with 10 μM compound. Inhibition studies conducted for CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP2A6, and CYP2E1 showed troglitazone to be the most nonselective and potent inhibitor followed by rosiglitazone and pioglitazone. In vitro, the thiazolidinediones were strong inhibitors of CYP2C8, withKi values between 1.7 and 5.6 μM, and of CYP3A4, with Ki values between 1.6 and 11.8 μM. Troglitazone, in addition, inhibited CYP2C9 (Ki 0.6 μM). Although the inhibitory effects of the thiazolidinediones have not been demonstrated clinically, our results suggest there is potential for interactions with CYP2C8 substrates. This is the first report of in vitro induction of P450 enzymes by rosiglitazone and pioglitazone. While only the induction of CYP3A4 by troglitazone has been demonstrated in vivo, these results suggest that other thiazolidinediones may have the potential to cause clinically significant drug interactions at sufficiently high doses.

Footnotes

  • ↵1 M. W. Sinz is presently at Bristol-Myers Squibb, Wallingford, CT 06422.

  • Abbreviations used are::
    PPAR
    peroxisome proliferator activated receptor
    P450
    cytochrome P450
    DMEM
    Dulbecco's Modified Eagle's medium
    • Received August 19, 2002.
    • Accepted December 20, 2002.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 31 (4)
Drug Metabolism and Disposition
Vol. 31, Issue 4
1 Apr 2003
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Comparative Effects of Thiazolidinediones on in Vitro P450 Enzyme Induction and Inhibition
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Comparative Effects of Thiazolidinediones on in Vitro P450 Enzyme Induction and Inhibition

Jasminder Sahi, Christopher B. Black, Geraldine A. Hamilton, Xianxian Zheng, Summer Jolley, Kelly A. Rose, Darryl Gilbert, Edward L. LeCluyse and Michael W. Sinz
Drug Metabolism and Disposition April 1, 2003, 31 (4) 439-446; DOI: https://doi.org/10.1124/dmd.31.4.439

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Comparative Effects of Thiazolidinediones on in Vitro P450 Enzyme Induction and Inhibition

Jasminder Sahi, Christopher B. Black, Geraldine A. Hamilton, Xianxian Zheng, Summer Jolley, Kelly A. Rose, Darryl Gilbert, Edward L. LeCluyse and Michael W. Sinz
Drug Metabolism and Disposition April 1, 2003, 31 (4) 439-446; DOI: https://doi.org/10.1124/dmd.31.4.439
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • TMDD Affects PK of IL-10 Fc-fusion Proteins
  • Uptake as the RDS in Pevonedistat Hepatic Clearance
  • In vitro downregulation of OATP1B1 by retinoids
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics